{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:04:16Z","timestamp":1789430656881,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2020-KH088685"],"award-info":[{"award-number":["RS-2020-KH088685"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00345897"],"award-info":[{"award-number":["RS-2024-00345897"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01556-1","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:55:59Z","timestamp":1782712559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Bon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Ju","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-5297","authenticated-orcid":false,"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-4401","authenticated-orcid":false,"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"1556_CR1","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"1556_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013\u201322.","journal-title":"Lancet Oncol"},{"key":"1556_CR3","first-page":"339","volume":"17","author":"Y Li","year":"2019","unstructured":"Li Y, Huang K, Liu L, Qu Y, Huang Y, Wu Y, et al. Effects of complement and serum IgG on rituximab\u2011dependent natural killer cell\u2011mediated cytotoxicity against Raji cells. Oncol Lett. 2019;17:339\u201347.","journal-title":"Oncol Lett"},{"key":"1556_CR4","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1182\/blood.V116.21.4919.4919","volume":"116","author":"MI Vega","year":"2010","unstructured":"Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Baritaki S, Bonavida B. An ADCC-independent mechanism of rituximab-mediated B-NHL cells depletion via sensitization to cell death through the expression of TRAIL on NK cells. Blood. 2010;116:4919\u20134919.","journal-title":"Blood"},{"key":"1556_CR5","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232\u201373.","journal-title":"Adv Ther"},{"key":"1556_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4143\/crt.2022.008","volume":"55","author":"JH Yi","year":"2023","unstructured":"Yi JH, Jeong SH, Kim SJ, Yoon DH, Kang HJ, Koh Y, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from two prospective Korean cohorts. Cancer Res Treat. 2023;55:325\u201333.","journal-title":"Cancer Res Treat"},{"key":"1556_CR7","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"1556_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s44313-024-00006-w","volume":"59","author":"N Warnnissorn","year":"2024","unstructured":"Warnnissorn N, Kanitsap N, Niparuck P, Boonsakan P, Kulalert P, Limvorapitak W, et al. Adding MYC\/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level. Blood Res. 2024;59:2.","journal-title":"Blood Res"},{"key":"1556_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"1556_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5045\/br.2023.2023177","volume":"58","author":"H Chung","year":"2023","unstructured":"Chung H, Cho H. Recent advances in cellular immunotherapy for lymphoid malignancies. Blood Res. 2023;58:166\u201372.","journal-title":"Blood Res"},{"key":"1556_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","volume":"24","author":"AR Rezvani","year":"2011","unstructured":"Rezvani AR, Maloney DG. Rituximab resistance. Best Pr Res Clin Haematol. 2011;24:203\u201316.","journal-title":"Best Pr Res Clin Haematol"},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14218\/OnA.2024.00006","volume":"2","author":"KW Kossow","year":"2024","unstructured":"Kossow KW, Bennett JG, Hoffmann MS. Mechanisms of immune evasion and novel treatments for relapsed and refractory diffuse large B-cell lymphoma. Oncol Adv. 2024;2:59\u201371.","journal-title":"Oncol Adv"},{"key":"1556_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.","journal-title":"J Extracell Vesicles"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.2147\/IJN.S325448","volume":"16","author":"S Zhu","year":"2021","unstructured":"Zhu S, Li S, Yi M, Li N, Wu K. Roles of microvesicles in tumor progression and clinical applications. Int J Nanomed. 2021;16:7071\u201390.","journal-title":"Int J Nanomed"},{"key":"1556_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2017.1340745","volume":"6","author":"K Menck","year":"2017","unstructured":"Menck K, Bleckmann A, Wachter A, Hennies B, Ries L, Schulz M, et al. Characterisation of tumour-derived microvesicles in cancer patients\u2019 blood and correlation with clinical outcome. J Extracell Vesicles. 2017;6:1340745.","journal-title":"J Extracell Vesicles"},{"key":"1556_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jmcb\/mju047","volume":"7","author":"K Menck","year":"2014","unstructured":"Menck K, Scharf C, Bleckmann A, Dyck L, Rost U, Wenzel D, et al. Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN. J Mol Cell Biol. 2014;7:143\u201353.","journal-title":"J Mol Cell Biol"},{"key":"1556_CR17","doi-asserted-by":"crossref","unstructured":"Menck K, Sivaloganathan S, Bleckmann A, Binder C. Microvesicles in cancer: small size, large potential. Int J Mol Sci. 2020:21:5373.","DOI":"10.3390\/ijms21155373"},{"key":"1556_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-11128-1","volume":"15","author":"LE Martinez","year":"2025","unstructured":"Martinez LE, Lensing S, Chang D, Magpantay LI, Guo Y, Mitsuyasu R, et al. CD20-bearing extracellular vesicles are associated with prognostic biomarkers of patients with AIDS-NHL. Sci Rep. 2025;15:25181.","journal-title":"Sci Rep"},{"key":"1556_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13046-018-0863-7","volume":"37","author":"Z Chen","year":"2018","unstructured":"Chen Z, You L, Wang L, Huang X, Liu H, Wei JY, et al. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo. J Exp Clin Cancer Res. 2018;37:190.","journal-title":"J Exp Clin Cancer Res"},{"key":"1556_CR20","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C Muller","year":"2012","unstructured":"Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276\u201384.","journal-title":"Blood"},{"key":"1556_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","volume":"123","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, Muller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640\u20136.","journal-title":"Blood"},{"key":"1556_CR22","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/annonc\/mdu208","volume":"25","author":"N Murawski","year":"2014","unstructured":"Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hanel M, Held G, et al. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol. 2014;25:1800\u20136.","journal-title":"Ann Oncol"},{"key":"1556_CR23","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/JCO.2013.54.6861","volume":"32","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;32:4127\u201333.","journal-title":"J Clin Oncol"},{"key":"1556_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14860","volume":"179","author":"M Pfreundschuh","year":"2017","unstructured":"Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hanel M, et al. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. Br J Haematol. 2017;179:410\u201320.","journal-title":"Br J Haematol"},{"key":"1556_CR25","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1007\/s13346-023-01370-3","volume":"13","author":"S Najafi","year":"2023","unstructured":"Najafi S, Majidpoor J, Mortezaee K. Extracellular vesicle\u2013based drug delivery in cancer immunotherapy. Drug Deliv Transl Res. 2023;13:2790\u2013806.","journal-title":"Drug Deliv Transl Res"},{"key":"1556_CR26","doi-asserted-by":"crossref","unstructured":"Taghikhani A, Farzaneh F, Sharifzad F, Mardpour S, Ebrahimi M Hassan ZM. Engineered tumor-derived extracellular vesicles: potentials in cancer immunotherapy. Front Immunol. 2020;11:221.","DOI":"10.3389\/fimmu.2020.00221"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01556-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:38:51Z","timestamp":1789429131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01556-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01556-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Most experiments in this study were conducted in vitro, and therefore additional ethical approval and informed consent were waived. However, primary tumor cells and serum samples obtained from patients enrolled in prospective cohort studies were used for translational analyses. This study was approved by the Institutional Review Board of Samsung Medical Center (approval No. 2022-12-139) and was conducted in accordance with the Declaration of Helsinki and Korean Good Clinical Practice guidelines.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"156"}}